Trial Profile
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs AMG 224 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 30 Nov 2020 Planned End Date changed from 15 Mar 2022 to 1 Sep 2023.